Patient considerations in the treatment of COPD: Focus on the new combination inhaler umeclidinium/vilanterol

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Medication adherence among patients with chronic diseases, such as COPD, may be suboptimal, and many factors contribute to this poor adherence. One major factor is the frequency of medication dosing. Once-daily dosing has been shown to be an important variable in medication adherence in chronic diseases, such as COPD. New inhalers that only require once-daily dosing are becoming more widely available. Combination once-daily inhalers that combine any two of the following three agents are now available: 1) a long-acting muscarinic antagonist; 2) a long acting beta2 agonist; and 3) an inhaled corticosteroid. A new once-daily inhaler with both a long-acting muscarinic antagonist, umeclidinium bromide, and a long acting beta2 agonist, vilanterol trifenatate, is now available worldwide for COPD treatment. It provides COPD patients convenience, efficacy, and a very favorable adverse-effects profile. Additional once-daily combination inhalers are available or will soon be available for COPD patients worldwide. The use of once-daily combination inhalers will likely become the standard maintenance management approach in the treatment of COPD because they improve medication adherence.

Original languageEnglish (US)
Pages (from-to)235-242
Number of pages8
JournalPatient Preference and Adherence
StatePublished - Feb 2 2015


  • Chronic obstructive pulmonary disease
  • Inhaled corticosteroid
  • Long-acting beta agonist
  • Long-acting muscarinic antagonist
  • Medication adherence

ASJC Scopus subject areas

  • Social Sciences (miscellaneous)
  • Medicine (miscellaneous)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)


Dive into the research topics of 'Patient considerations in the treatment of COPD: Focus on the new combination inhaler umeclidinium/vilanterol'. Together they form a unique fingerprint.

Cite this